A Phase 3 interventional study of Pneumococcal conjugate vaccine GSK1024850A and Infanrix hexa in Infections, Streptococcal, sponsored by GlaxoSmithKline. Completed at 8 sites in 2 countries. Open to participants aged 8 Weeks to 16 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-17.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Streptococcal Infections by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Streptococcal Infections · GlaxoSmithKline.
Among the 64 studies in Streptococcal Infections by GlaxoSmithKline, this one is the 36th largest by enrollment of the 55 interventional ones that give a count, is one of 9 that started in 2006, is one of 38 in phase 3, and was the 12th registered.
147 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.
Browse Streptococcal Infections studies →1 of the 64 studies in Streptococcal Infections by GlaxoSmithKline is open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Australia
Ages 18–25 · Healthy volunteers
By country, each count listing its studies:
Of the 10 Streptococcal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 8 Weeks to 16 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 9 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 286 is close to the median of 270 across 106 interventional studies indexed under Streptococcal Infections.
Median enrollment 365 across the 55 interventional studies, 50 across the 9 observational. Of the 61 that completed or were terminated, 44 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
1 of the studies in Streptococcal Infections by GlaxoSmithKline that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07085702GlaxoSmithKlineA Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults | 2027-06-29 |
Add it to your calendar (.ics) → With an account.
Among the 64 studies in Streptococcal Infections by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with diphtheria, tetanus, acellular pertussis-hepatitis B virus-inactivated polio virus/Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) vaccine in preterm infants as a 3-dose primary immunization course during the first 6 months of life.
This protocol posting deals with objectives \& outcome measures of the primary study. The objectives \& outcome measures of the Booster study are presented in a separate protocol posting (NCT number = 00609492)
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Very preterm infants born after a gestation period of 27-30 weeks (189-216 days)
Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa
Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)
Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa
Infants born after a gestation period of more than 36 weeks (more than 258 days)
Biological: Pneumococcal conjugate vaccine GSK1024850A · Biological: Infanrix hexa
Intramuscular injection, 3 doses
Intramuscular injection, 3 doses
Also known as: DTPa-HBV-IPV/Hib
Number of Subjects With Core Fever (Rectal Temperature) Greater Than (>) the Cut-off
Fever was measured as rectal temperature. Assessment of occurrences of fever \> 39.0 °C was performed post doses 1, 2 and 3 of Synflorix or Infanrix hexa vaccine.
Time frame: Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Solicited local symptoms assessed included pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\>) 30 millimeters (mm). "Any" was defined as incidence of the specified symptom regardless of intensity.
Time frame: Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)
Number of Subjects With Any and Grade 3 Solicited General Symptoms
Solicited general symptoms assessed included drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. "Any" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.
Time frame: Within 4 days (Days 0-3) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)
Number of Subjects With Any Unsolicited Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
Time frame: Within 31 days (Days 0-30) after each vaccine dose, administered according to a 3-dose schedule at 2-4-6 months of age (Month 0-2-4)
Number of Subjects With Any Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
Time frame: Throughout the active phase of the study (from the first vaccine administration (Month 0) up to 1 month after the third vaccine administration (Month5).
Number of Subjects With Any Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
Time frame: Throughout the entire study period starting from the first vaccine dose administration (Month 0) up to the end of the 6-month safety follow-up (ESFU- Month 10).
Number of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Greater Than or Equal to (≥) the Cut-off
The cut-off for the assay was ≥ 0.20 microgram per mililiter (μg/ mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off
The cut-off for the assay was ≥ 0.05 microgram per mililiter (μg/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off
The cut-off for the assay was ≥ 8
Time frame: One month after the 3rd vaccine dose (Month 5)
Opsonophagocytic Activity Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F
Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off
The cut-off for the assay was ≥ 0.05 microgram per milliliter (μg/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A
Seropositivity status was defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off
The cut-off for the assay was ≥ 8.
Time frame: One month after the 3rd vaccine dose (Month 5)
Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A
Seropositivity status was defined as opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Concentrations of Antibodies Against Protein D (Anti-PD) ≥ the Cut-off
The cut-off for the assay was ≥ 100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Concentrations of Antibodies Against Protein D (Anti-PD)
Seropositivity status was defined as anti-PD antibody concentrations ≥ 100 ELISA units per milliliter ( EL.U/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Anti-diphtheria (Anti DT) and Anti-tetanus Toxoids (Anti TT) Antibody Concentrations ≥ the Cut-off
The cut-off for the assay was ≥ 0.1 international units per milliliter (IU/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Antibody Concentrations for Anti-diphtheria and Tetanus Toxoids ≥ the Cut-off
Seroprotection status was defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 IU/mL
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off
The cut-off for the assay was ≥ 0.15 microgram per milliliter (μg/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off
The cut-off for the assay was ≥ 1.0 microgram per milliliter (μg/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations ≥ th Cut-off
Seroprotection status was defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations ≥ the Cut-off
The cut-off for the assay was ≥ 5 ELISA unit per milliliter (EL.U/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Antibody Concentration for Anti-pertussis Toxoid (Anti-PT) , Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)
Seropositivity status was defined as anti-PT, anti-FHA, anti-PRN antibody concentrations ≥ 5 EL.U/mL.
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off.
The cut-off for the assay was ≥ 10 milli-international units per milliliter (mIU/mL).
Time frame: One month after the 3rd vaccine dose (Month 5)
Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations
Seroprotection status was defined as Anti-HBs antibody concentrations ≥ 10 mIU/mL
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Anti-polio Type 1, 2 and 3 Antibody Titres
The cut-off for the assay was ≥ 8.
Time frame: One month after the 3rd vaccine dose (Month 5)
Antibody Titers for Polio Type 1, 2 and 3 ≥ the Cut-off
Seroprotection status was defined as Anti-polio type 1, Anti-polio type 2 and Anti-polio type 3 antibody titers ≥ 8.
Time frame: One month after the 3rd vaccine dose (Month 5)
Number of Subjects With Vaccine Response to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN)
Vaccine response to PT, FHA and PRN was defined as appearance of antibodies in subjects who are initially seronegative (S-), or at least maintenance of pre-vaccination antibody concentrations in those who are initially seropositive (S+). For the SYNFLORIX™ + INFANRIX™ HEXA GROUP I, no subjects presented initial seropositivity for PT and PRN antigens.
Time frame: One month after the 3rd vaccine dose (Month 5)
For each subject the study duration was approximately 5 months for the active phase (Month 0 untill one month after last vaccination) and 10 months, including the 5 months extended safety follow-up.
| Milestone | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Started | 50 | 87 | 149 |
| Completed | 48 | 83 | 139 |
| Not completed | 2 | 4 | 10 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 5 |
| Withdrew: Withdrawal by subject | 1 | 3 | 2 |
| Withdrew: Migrated/moved from study area | 0 | 0 | 3 |
Fever was measured as rectal temperature. Assessment of occurrences of fever \> 39.0 °C was performed post doses 1, 2 and 3 of Synflorix or Infanrix hexa vaccine.
| Participants | Synflorix™ + Infanrix™ Hexa Group III | Pooled Group I + II |
|---|---|---|
| Fever > 39.0°C, post Dose 1 | 5 | 2 |
| Fever > 39.0°C, post Dose 2 | 1 | 1 |
| Fever > 39.0°C, post Dose 3 | 3 | 1 |
Solicited local symptoms assessed included pain, redness and swelling. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (\>) 30 millimeters (mm). "Any" was defined as incidence of the specified symptom regardless of intensity.
| Participants | Synflorix™ + Infanrix™ Hexa Group III | Pooled Group I + II |
|---|---|---|
| Any pain, Post Dose 1 | 58 | 40 |
| Grade 3 pain, Post Dose 1 | 6 | 6 |
| Any redness, Post Dose 1 | 67 | 39 |
| Grade 3 redness, Post Dose 1 | 0 | 1 |
| Any swelling, Post Dose 1 | 67 | 30 |
| Grade 3 swelling, Post Dose 1 | 2 | 1 |
| Any pain, Post Dose 2 | 39 | 39 |
| Grade 3 pain, Post Dose 2 | 1 | 9 |
| Any redness, Post Dose 2 | 72 | 41 |
| Grade 3 redness, Post Dose 2 | 7 | 0 |
| Any swelling, Post Dose 2 | 60 | 30 |
| Grade 3 swelling, Post Dose 2 | 4 | 0 |
| Any pain, Post Dose 3 | 42 | 30 |
| Grade 3 pain, Post Dose 3 | 6 | 3 |
| Any redness, Post Dose 3 | 66 | 33 |
| Grade 3 redness, Post Dose 3 | 9 | 3 |
| Any swelling, Post Dose 3 | 58 | 24 |
| Grade 3 swelling, Post Dose 3 | 6 | 2 |
Solicited general symptoms assessed included drowsiness, fever (defined as rectal temperature ≥ 38.0°C), irritability, and loss of appetite. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) above (\>) 40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all. "Any" was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination.
| Participants | Synflorix™ + Infanrix™ Hexa Group III | Pooled Group I + II |
|---|---|---|
| Any drowsiness, Post Dose 1 | 53 | 44 |
| Grade 3 drowsiness, Post Dose 1 | 2 | 1 |
| Any fever(rectally), Post Dose 1 | 38 | 41 |
| Grade 3 fever(rectally), Post Dose 1 | 1 | 0 |
| Any irritability, Post Dose 1 | 73 | 53 |
| Grade 3 irritability, Post Dose 1 | 9 | 6 |
| Any loss of appetite, Post Dose 1 | 36 | 33 |
| Grade 3 loss of appetite, Post Dose 1 | 0 | 0 |
| Any drowsiness, Post Dose 2 | 34 | 32 |
| Grade 3 drowsiness, Post Dose 2 | 0 | 1 |
| Any fever(rectally), Post Dose 2 | 34 | 40 |
| Grade 3 fever(rectally), Post Dose 2 | 0 | 0 |
| Any irritability, Post Dose 2 | 53 | 51 |
| Grade 3 irritability, Post Dose 2 | 2 | 4 |
| Any loss of appetite, Post Dose 2 | 23 | 35 |
| Grade 3 loss of appetite, Post Dose 2 | 0 | 2 |
| Any drowsiness, Post Dose 3 | 22 | 18 |
| Grade 3 drowsiness, Post Dose 3 | 1 | 4 |
| Any fever(rectally), Post Dose 3 | 25 | 16 |
| Grade 3 fever(rectally), Post Dose 3 | 1 | 0 |
| Any irritability, Post Dose 3 | 44 | 40 |
| Grade 3 irritability, Post Dose 3 | 1 | 3 |
| Any loss of appetite, Post Dose 3 | 22 | 26 |
| Grade 3 loss of appetite, Post Dose 3 | 0 | 1 |
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. "Any" was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.
| Participants | Synflorix™ + Infanrix™ Hexa Group III | Pooled Group I + II |
|---|---|---|
| Number of Subjects With Any Unsolicited Adverse Events (AEs) | 58 | 43 |
Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
| Participants | Synflorix™ + Infanrix™ Hexa Group III | Pooled Group I + II |
|---|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs) | 13 | 18 |
Serious adverse events (SAEs) assessed included medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.
| Participants | Synflorix™ + Infanrix™ Hexa Group III | Pooled Group I + II |
|---|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs) | 19 | 29 |
The cut-off for the assay was ≥ 0.20 microgram per mililiter (μg/ mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-1 | 41 | 82 | 129 |
| Anti-4 | 40 | 81 | 130 |
| Anti-5 | 42 | 82 | 129 |
| Anti-6B | 38 | 78 | 123 |
| Anti-7F | 41 | 82 | 131 |
| Anti-9V | 40 | 82 | 132 |
| Anti-14 | 41 | 82 | 132 |
| Anti-18C | 41 | 81 | 130 |
| Anti-19F | 42 | 82 | 132 |
| Anti-23F | 39 | 79 | 125 |
The cut-off for the assay was ≥ 0.05 microgram per mililiter (μg/mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-1 | 42 | 82 | 130 |
| Anti-4 | 41 | 82 | 130 |
| Anti-5 | 42 | 82 | 129 |
| Anti-6B | 40 | 81 | 131 |
| Anti-7F | 41 | 82 | 131 |
| Anti-9V | 41 | 82 | 132 |
| Anti-14 | 41 | 82 | 132 |
| Anti-18C | 41 | 81 | 131 |
| Anti-19F | 42 | 82 | 132 |
| Anti-23F | 39 | 81 | 129 |
Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).
| μg/mL | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-1 | 0.97 (0.75 to 1.26) | 1.1 (0.93 to 1.3) | 1.35 (1.18 to 1.55) |
| Anti-4 | 1.53 (1.19 to 1.98) | 1.88 (1.61 to 2.2) | 2.42 (2.13 to 2.74) |
| Anti-5 | 1.45 (1.13 to 1.86) | 1.93 (1.65 to 2.25) | 2.31 (2 to 2.66) |
| Anti-6B | 0.85 (0.61 to 1.19) | 1.11 (0.89 to 1.37) | 1.18 (1 to 1.39) |
| Anti-7F | 1.87 (1.47 to 2.39) | 2.37 (2.07 to 2.73) | 2.69 (2.39 to 3.03) |
| Anti-9V | 1.43 (1.17 to 1.74) | 1.69 (1.44 to 1.99) | 2.41 (2.13 to 2.73) |
| Anti-14 | 3.52 (2.81 to 4.42) | 3.28 (2.77 to 3.89) | 3.71 (3.21 to 4.3) |
| Anti-18C | 3.28 (2.51 to 4.29) | 4.86 (3.92 to 6.02) | 5.22 (4.27 to 6.38) |
| Anti-19F | 3.6 (2.83 to 4.57) | 4.8 (4.15 to 5.55) | 4.56 (3.95 to 5.26) |
| Anti-23F | 1.05 (0.74 to 1.49) | 1.33 (1.07 to 1.65) | 1.54 (1.28 to 1.85) |
The cut-off for the assay was ≥ 8
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Opsono-1 | 20 | 49 | 80 |
| Opsono-4 | 36 | 72 | 110 |
| Opsono-5 | 29 | 69 | 104 |
| Opsono-6B | 30 | 59 | 85 |
| Opsono-7F | 36 | 74 | 113 |
| Opsono-9V | 36 | 72 | 103 |
| Opsono-14 | 36 | 73 | 110 |
| Opsono-18C | 34 | 65 | 99 |
| Opsono-19F | 31 | 71 | 105 |
| Opsono-23F | 35 | 70 | 109 |
Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.
| Titers | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Opsono-1 | 23 (13 to 40.6) | 30.3 (20.5 to 44.8) | 46.3 (33.4 to 64.1) |
| Opsono-4 | 644.1 (474.6 to 874) | 500.9 (384.5 to 652.5) | 543.5 (450.6 to 655.5) |
| Opsono-5 | 45.2 (27.7 to 73.8) | 70.8 (52.3 to 95.7) | 94.8 (75.7 to 118.7) |
| Opsono-6B | 278.3 (125.5 to 617.3) | 305.1 (180.1 to 516.9) | 268.2 (167.5 to 429.4) |
| Opsono-7F | 4086.3 (2834.3 to 5891.3) | 3047.3 (2422.2 to 3833.7) | 2395.2 (1973.2 to 2907.5) |
| Opsono-9V | 930.5 (603.1 to 1435.6) | 837.9 (642.7 to 1092.3) | 1144.8 (922.3 to 1421) |
| Opsono-14 | 775.4 (539 to 1115.5) | 901.6 (699.8 to 1161.6) | 644.6 (514.9 to 807) |
| Opsono-18C | 262.5 (159.4 to 432.4) | 321.5 (220.9 to 467.7) | 251 (189 to 333.4) |
| Opsono-19F | 104.2 (61.5 to 176.5) | 201.1 (149.7 to 270.1) | 182.7 (139.2 to 239.7) |
| Opsono-23F | 1659.4 (975.1 to 2824) | 1147.2 (843 to 1561.2) | 1558.8 (1302.6 to 1865.3) |
The cut-off for the assay was ≥ 0.05 microgram per milliliter (μg/mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-6A | 32 | 68 | 114 |
| Anti-19A | 26 | 72 | 120 |
Seropositivity status was defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).
| μg/mL | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-6A | 0.14 (0.09 to 0.2) | 0.21 (0.15 to 0.28) | 0.2 (0.16 to 0.25) |
| Anti-19A | 0.08 (0.06 to 0.11) | 0.21 (0.16 to 0.28) | 0.26 (0.21 to 0.32) |
The cut-off for the assay was ≥ 8.
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Opsono-6A | 25 | 54 | 58 |
| Opsono-19A | 2 | 10 | 17 |
Seropositivity status was defined as opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.
| Titers | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Opsono-6A | 114.5 (52.8 to 248.5) | 157.3 (95.8 to 258.4) | 49.5 (31.8 to 76.9) |
| Opsono-19A | 4.5 (3.8 to 5.4) | 7.1 (4.9 to 10.1) | 7 (5.4 to 9.2) |
The cut-off for the assay was ≥ 100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Number of Subjects With Concentrations of Antibodies Against Protein D (Anti-PD) ≥ the Cut-off | 42 | 82 | 130 |
Seropositivity status was defined as anti-PD antibody concentrations ≥ 100 ELISA units per milliliter ( EL.U/mL).
| EL.U/mL | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Concentrations of Antibodies Against Protein D (Anti-PD) | 1688.6 (1320.1 to 2159.8) | 1415.4 (1167.1 to 1716.5) | 1496.8 (1283.4 to 1745.8) |
The cut-off for the assay was ≥ 0.1 international units per milliliter (IU/mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-diphtheria | 18 | 41 | 61 |
| Anti-tetanus | 18 | 41 | 61 |
Seroprotection status was defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 IU/mL
| IU/mL | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-diphtheria | 2.495 (1.664 to 3.741) | 3.23 (2.628 to 3.969) | 3.077 (2.481 to 3.817) |
| Anti-tetanus | 7.745 (6.284 to 9.545) | 8.617 (7.216 to 10.29) | 7.695 (6.838 to 8.66) |
The cut-off for the assay was ≥ 0.15 microgram per milliliter (μg/mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off | 18 | 41 | 63 |
The cut-off for the assay was ≥ 1.0 microgram per milliliter (μg/mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off | 16 | 38 | 60 |
Seroprotection status was defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL
| μg/mL | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations ≥ th Cut-off | 4.031 (2.261 to 7.184) | 5.804 (4.12 to 8.178) | 7.952 (5.839 to 10.831) |
The cut-off for the assay was ≥ 5 ELISA unit per milliliter (EL.U/mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-PT | 18 | 41 | 61 |
| Anti-FHA | 18 | 41 | 61 |
| Anti-PRN | 17 | 40 | 60 |
Seropositivity status was defined as anti-PT, anti-FHA, anti-PRN antibody concentrations ≥ 5 EL.U/mL.
| EL.U/mL | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-PT | 41.9 (27.6 to 63.7) | 37.9 (30.7 to 46.7) | 47.3 (40.2 to 55.7) |
| Anti-FHA | 188.6 (133.4 to 266.6) | 169 (139.6 to 204.7) | 163.1 (138.3 to 192.3) |
| Anti-PRN | 127.6 (81.5 to 199.6) | 109.1 (85.7 to 139) | 119.1 (101.1 to 140.4) |
The cut-off for the assay was ≥ 10 milli-international units per milliliter (mIU/mL).
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Number of Subjects With Anti-Hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off. | 8 | 26 | 12 |
Seroprotection status was defined as Anti-HBs antibody concentrations ≥ 10 mIU/mL
| mIU/mL | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations | 431.9 (240.7 to 775.2) | 356 (221.1 to 573.4) | 462.9 (221.1 to 969.1) |
The cut-off for the assay was ≥ 8.
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-Polio 1 | 12 | 22 | 29 |
| Anti-Polio 2 | 12 | 22 | 29 |
| Anti-Polio 3 | 10 | 21 | 29 |
Seroprotection status was defined as Anti-polio type 1, Anti-polio type 2 and Anti-polio type 3 antibody titers ≥ 8.
| Titers | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-Polio 1 | 271.3 (132.9 to 554) | 189.5 (109.9 to 326.8) | 230.1 (166 to 319) |
| Anti-Polio 2 | 341.7 (214 to 545.6) | 319 (172.5 to 589.8) | 194.4 (121.7 to 310.7) |
| Anti-Polio 3 | 248.4 (67.9 to 908.7) | 344.7 (192.2 to 618.3) | 384.8 (245.3 to 603.6) |
Vaccine response to PT, FHA and PRN was defined as appearance of antibodies in subjects who are initially seronegative (S-), or at least maintenance of pre-vaccination antibody concentrations in those who are initially seropositive (S+). For the SYNFLORIX™ + INFANRIX™ HEXA GROUP I, no subjects presented initial seropositivity for PT and PRN antigens.
| Participants | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| Anti-PT, S- | 18 | 27 | 45 |
| Anti-PT, S+ | 0 | 8 | 12 |
| Anti-FHA, S- | 15 | 22 | 18 |
| Anti-FHA, S+ | 3 | 17 | 41 |
| Anti-PRN, S- | 17 | 34 | 45 |
| Anti-PRN, S+ | 0 | 4 | 12 |
Collected over Solicited local and general symptoms: during the 4-day post vaccination; Unsolicited AEs: during the 31-day post vaccination; SAEs: during the whole study period (Month 0 - Month 10, including the 5 months extended safety follow-up).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Synflorix™ + Infanrix™ Hexa Group I | 1/50 (2%) | 17/50 (34%) | 42/50 (84%) |
| Synflorix™ + Infanrix™ Hexa Group II | 0/87 (0%) | 11/87 (12.6%) | 76/87 (87.4%) |
| Synflorix™ + Infanrix™ Hexa Group III | 0/149 (0%) | 19/149 (12.8%) | 136/149 (91.3%) |
| Event | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| BronchiolitisInfections and infestations | 4/50 | 1/87 | 3/149 |
| GastroenteritisInfections and infestations | 3/50 | 0/87 | 3/149 |
| PneumoniaInfections and infestations | 2/50 | 0/87 | 1/149 |
| Breath holdingPsychiatric disorders | 0/50 | 2/87 | 0/149 |
| TachypnoeaRespiratory, thoracic and mediastinal disorders | 0/50 | 2/87 | 0/149 |
| ThrombocythaemiaBlood and lymphatic system disorders | 1/50 | 0/87 | 0/149 |
| Inguinal hernia, obstructiveGastrointestinal disorders | 1/50 | 0/87 | 0/149 |
| VomitingGastrointestinal disorders | 1/50 | 0/87 | 0/149 |
| IrritabilityGeneral disorders | 1/50 | 0/87 | 0/149 |
| PyrexiaGeneral disorders | 1/50 | 0/87 | 2/149 |
| Event | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III |
|---|---|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 24/50 | 49/87 | 102/149 |
| IrritabilityPsychiatric disorders | 22/50 | 53/87 | 100/149 |
| SwellingGeneral disorders | 20/50 | 35/87 | 98/149 |
| PainGeneral disorders | 24/50 | 41/87 | 84/149 |
| Decreased appetiteMetabolism and nutrition disorders | 19/50 | 46/87 | 51/149 |
| PyrexiaGeneral disorders | 22/50 | 45/87 | 71/149 |
| SomnolenceNervous system disorders | 20/50 | 44/87 | 65/149 |
| Upper respiratory tract infectionInfections and infestations | 1/50 | 9/87 | 10/149 |
| Injection site noduleGeneral disorders | 0/50 | 4/87 | 10/149 |
| Age, Continuous(Weeks) | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III | Total |
|---|---|---|---|---|
| Mean | 11.0 ± 3.2 | 9.5 ± 1.45 | 9.3 ± 1.45 | 9.66 ± 1.97 |
| Sex: Female, Male(Participants) | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III | Total |
|---|---|---|---|---|
| Female | 19 | 40 | 62 | 121 |
| Male | 31 | 47 | 87 | 165 |
| Race/Ethnicity, Customized(Participants) | Synflorix™ + Infanrix™ Hexa Group I | Synflorix™ + Infanrix™ Hexa Group II | Synflorix™ + Infanrix™ Hexa Group III | Total |
|---|---|---|---|---|
| Race/Etnicity — White - Caucasian/ European heritage | 36 | 77 | 140 | 253 |
| Race/Etnicity — African heritage/ African american | 2 | 1 | 4 | 7 |
| Race/Etnicity — American Indian or Alaskan native | 4 | 6 | 2 | 12 |
| Race/Etnicity — Asian - south east Asian heritage | 0 | 1 | 0 | 1 |
| Race/Etnicity — White - Arabic/ north African heritage | 1 | 0 | 2 | 3 |
| Race/Etnicity — Other (unspecified) | 7 | 2 | 1 | 10 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Oct 2006 to primary completion in Jul 2007, 9 months.
Results were first posted in Dec 2018, 11 years 5 months after primary completion. A results delay was requested in May 2009.
Of 28 industry-sponsored phase 3 interventional studies under Streptococcal Infections, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 13. This study's 9 months is close to that.
Counting every sponsor, half of 29 studies reached it within 10 months; a quarter within 8 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine